COVID-19.рф: ИНФОРМАЦИЯ ПРОТИВ ПАНДЕМИИ

Поиск по репозиторию

Статья

Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases

L. von, J. Vehreschild, O. Cornely, L. Pagano, F. Compagno, A. Pagliuca, H. Akan, K. Lagrou, L. Pagano, M. Hoenigl, N. Klimko, O. Cornely, P. Verweij, R. Duarte, S. Zimmerli, S. Bretagne, Z. Racil, H. Hirsch, I. EHA,
2021
https://doi.org/10.1038/s41375-020-0832-y

Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease. © 2020, The Author(s).

Цитирование

Похожие публикации

Recommendations for return to sport during the SARS-CoV-2 pandemic
H. Löllgen, N. Bachl, T. Papadopoulou,
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
C. Riggioni, P. Comberiati, M. Giovannini,
Angiotensin-Converting Enzyme Type 2 as a Molecular Mediator for Infection of Cells with SARS-CoV and SARS-CoV-2 Viruses
A. Shpakov,

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • L. von
    Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
  • J. Vehreschild
    Leibniz-Institut für Infektionsbiologie und Naturstoff Forschung, Hans-Knöll Institut, Jena, Germany
  • O. Cornely
    Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany
  • L. Pagano
    Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
  • F. Compagno
    German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany
  • A. Pagliuca
    Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
  • H. Akan
    Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany
  • K. Lagrou
    EHA Infectious Diseases Scientific Working Group, Cologne, Germany
  • L. Pagano
    Department of Hematology, Fondazione Policlinico Universitario A. Gemelli—IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy
  • M. Hoenigl
    Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
  • N. Klimko
    Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
  • O. Cornely
    Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland
  • P. Verweij
    Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
  • R. Duarte
    Department of Haematological Medicine, King’s College Hospital NHS Foundation Trust, London, United Kingdom
  • S. Zimmerli
    Hematology Clinical Research Unit, Ankara University, Cebeci Campus, Ankara, Turkey
  • S. Bretagne
    Laboratory of Clinical Bacteriology and Mycology, Department of Microbiology, Immunology and Transplantation, Excellence Center for Medical Mycology (ECMM), KU Leuven, Leuven, Belgium
  • Z. Racil
    Department of Internal Medicine, Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria
  • H. Hirsch
    Department of Clinical Mycology, Allergology and Immunology, North Western State Medical University, St. Petersburg, Russian Federation
  • I. EHA
    Department of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, Netherlands
Название журнала
  • Leukemia
Том
  • 34
Выпуск
  • 6
Страницы
  • 1487-1494
Ключевые слова
  • chloroquine; granulocyte colony stimulating factor; immunoglobulin; lopinavir plus ritonavir; remdesivir; ribavirin; ruxolitinib; steroid; tocilizumab; Article; chemotherapy; coronavirus disease 2019; diagnostic procedure; disease control; disease course; disease severity; general practitioner; health care management; hematologist; hematology; human; immunosuppressive treatment; infection prevention; infection risk; lower respiratory tract infection; malignant neoplasm; oncologist; patient safety; pediatrics; priority journal; respiratory tract infection; Severe acute respiratory syndrome coronavirus 2; Betacoronavirus; Coronavirus infection; disease transmission; infection control; neoplasm; pandemic; patient care; practice guideline; prevention and control; procedures; virology; virus pneumonia; Betacoronavirus; Coronavirus Infections; Humans; Infection Control; Infectious Disease Transmission, Patient-to-Professional; Neoplasms; Pandemics; Patient Care; Pneumonia, Viral; Practice Guidelines as Topic
Издатель
  • Springer Nature
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus
COVID-19.рф: Информация против пандемии

Адрес: 115114, Москва, ул. Летниковская, д. 4, стр.5, офис 2.4
тел.\факс: +7(499)754-99-94, доб. 502
e-mail: covid19@neicon.ru

Проект реализуется с использованием гранта Президента Российской Федерации на развитие гражданского общества, предоставленного Фондом президентских грантов.

Содержимое сайта, если не указано иное, опубликовано в соответствии с лицензией Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная (CC BY 4.0). Права на материалы, переданные партнерами проекта, принадлежат их правообладателям.

© 2025 NEICON